Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.40 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.39 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.39 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1221396 | 1.00 | SLC6A4 (0.48) | SLC6A4SLC6A2KCNH2SLC6A3SLC6A1 | |
| SCHEMBL1189935 | 1.00 | SLC6A4 (0.48) | SLC6A4SLC6A2KCNH2SLC6A3SLC6A1 | |
| Hydrochloric Acid SCHEMBL4469742 | 0.98 | SLC6A4 (0.47) | SLC6A4SLC6A2KCNH2SLC6A3SLC6A1 | |
| Hydrochloric Acid SCHEMBL4469740 | 0.98 | SLC6A4 (0.47) | SLC6A4SLC6A2KCNH2SLC6A3SLC6A1 | |
| Hydrochloric Acid SCHEMBL2013500 | 0.98 | SLC6A4 (0.47) | SLC6A4SLC6A2KCNH2SLC6A3SLC6A1 | |
| SCHEMBL25222580 | 0.88 | SLC6A1 (0.47) | SLC6A4SLC6A2KCNH2SLC6A3SLC6A1 | |
| SCHEMBL4017478 | 0.88 | SLC6A1 (0.47) | SLC6A4SLC6A2KCNH2SLC6A3SLC6A1 | |
| SCHEMBL477375 | 0.88 | SLC6A1 (0.47) | SLC6A4SLC6A2KCNH2SLC6A3SLC6A1 | |
| SCHEMBL477248 | 0.87 | GABRA5 (0.44) | SLC6A4SLC6A2KCNH2SLC6A3SLC6A1 | |
| Hydrochloric Acid SCHEMBL4014841 | 0.86 | SLC6A1 (0.46) | SLC6A4SLC6A2KCNH2SLC6A3SLC6A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3867248-B1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-12-10 | — | — | EP | disclosed |
| US-20250115587-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2025-04-10 | — | — | US | disclosed |
| US-12234227-B2 | Pyrazole derivatives as H4 antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-02-25 | — | — | US | disclosed |
| WO-2024245406-A1 | 1H-[1,2,3]TRIAZOLO[4,5-H]QUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | 成都赛璟生物医药科技有限公司 | 2024-12-05 | — | — | WO | disclosed |
| EP-4395892-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4395891-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118234724-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2024054512-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-7045528-B2 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20060079548-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2006-04-13 | — | — | US | disclosed |
| US-20050070508-A1 | Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| EP-1515975-A1 | BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-6869962-B2 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-03-22 | — | — | US | disclosed |
| WO-2005021553-A1 | NAPHTHALENE CARBOXAMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| US-20040186126-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| US-20040009965-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003106462-A1 | BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234227-B2 | Pyrazole derivatives as H4 antagonist compounds | HRH4, HRH3, HRH2 | SLC6A4 656/4885SLC6A2 1414/4885KCNH2 597/4885 |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | SLC6A4 1157/4885SLC6A2 792/4885KCNH2 611/4885 |
| US-20040186126-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | DPYD, DHFR, TYMP | SLC6A4 3749/4885SLC6A2 4294/4885KCNH2 2716/4885 |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | HTT, HYPK, ATXN2 | SLC6A4 40/4885SLC6A2 119/4885KCNH2 3605/4885 |
| US-20050070508-A1 | Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents | CCNA1, CCNA2, CCNT1 | SLC6A4 4027/4885SLC6A2 2976/4885KCNH2 4406/4885 |
| US-20040009965-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | DPYD, DHFR, TYMP | SLC6A4 3749/4885SLC6A2 4294/4885KCNH2 2716/4885 |
| US-20060079548-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | TPD52L2, DPYD, CCND2 | SLC6A4 2298/4885SLC6A2 3892/4885KCNH2 2785/4885 |
| US-20250115587-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | HRH4, HRH3, HDAC3 | SLC6A4 595/4885SLC6A2 1180/4885KCNH2 935/4885 |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | SLC6A4 4837/4885SLC6A2 4863/4885KCNH2 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.